Metabolomics: From liver chiromancy to personalized precision medicine in advanced chronic liver disease

Procopeţ, Bogdan; Fischer, Petra; Farcau, Oana; Ştefănescu, Horia

doi:10.4254/wjh.v10.i3.371

Cited by 11 publications

(9 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding liver disease, it has been described that chronic hepatic disease itself alters fatty acid metabolism promoted by gut microbiota, 37 among others. Additionally, increased glycerol levels have been previously found in advanced chronic liver disease and hepatocellular carcinoma 38 . Thus, according to our results, cirrhotic HIV/HCV‐ and HCV‐infected patients showed a similar profile to that described for advanced cirrhosis of different aetiologies.…”

Section: Discussionsupporting

confidence: 88%

Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV‐coinfected and HCV‐monoinfected patients

Salgüero

Rojo

Berenguer

et al. 2020

Liver International

View full text Add to dashboard Cite

Background & Aims Hepatitis C virus (HCV), human immunodeficiency virus (HIV) and cirrhosis induce metabolic disorders. Here, we aimed to evaluate the association of plasma metabolites with Child‐Turcotte‐Pugh (CTP) score and hepatic decompensation in HIV/HCV‐coinfected and HCV‐monoinfected patients with advanced cirrhosis. Methods A cross‐sectional study was carried out in 62 HIV/HCV‐coinfected and 28 HCV‐monoinfected patients. Metabolomics analysis was performed by gas chromatography‐mass spectrometry (GC‐MS) and liquid chromatography‐mass spectrometry (LC‐MS). The statistical association analysis was performed by partial least squares discriminant analysis (PLS‐DA) and generalized linear model (GLM) with binomial distribution (to analyse HIV coinfection, high alcohol intake, treatment with statins, previous HCV therapy failure and decompensation) and ordinal logistic regression (OLR) models to analyse different stages of cirrhosis (CTP score). Results The statistical analysis identified plasma metabolites associated with HIV coinfection, high alcohol intake, CTP score and hepatic decompensation. Overall, fatty acids, bile acids, aromatic and sulphur amino acids, butyrate derivatives, oxidized phospholipids, energy‐related metabolites and bacterial fermentation‐related metabolites were increased in more advanced cirrhosis stages; while lysophosphatidylcholines and lysophosphatidylethanolamines, branched‐chain amino acids (BCAA) and metabolites of tricarboxylic acid cycle, among others, were decreased in more advanced cirrhosis. Most of the significant metabolites displayed a similar trend after stratifying for HIV/HCV‐ and HCV‐infected patients. Glycolic acid, LPC (16:0) and taurocholic acid had high accuracy for discriminating patients according to decompensated cirrhosis (CTP ≥ 7). Conclusion Altered plasma metabolomic profile was associated with advanced stages of cirrhosis in HIV/HCV‐coinfected and HCV‐monoinfected patients.

show abstract

Section: Discussionsupporting

confidence: 88%

Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV‐coinfected and HCV‐monoinfected patients

Salgüero

Rojo

Berenguer

et al. 2020

Liver International

View full text Add to dashboard Cite

show abstract

“…As most of compounds pass through the liver after intestine absorption, this organ is a key regulator of many circulating metabolites, empowering the possibility to relate their serum levels to liver physiopathology. The small biocompounds (usually <1kDa molecules) profiles in chronic liver diseases including HCC have been investigated by NMR , but still there are no biomarkers able to predict time to recurrence after locoregional treatments that could be translated to clinical practice 89 .…”

Section: Uninvestigated Potential Biomarkersmentioning

confidence: 99%

Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma

Canale

Ulivi

Foschi³

et al. 2018

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Radiofrequency ablation (RFA) is an effective local treatment for curative intent in patients with cirrhosis of the liver and hepatocellular carcinoma (HCC) with diameter <3 cm. Several meta-analyses have shown that RFA and surgical resection are comparable in terms of their impact on overall survival. The only clinical data available on markers that are predictive of recurrence and survival after RFA treatment are based on retrospective observational studies. Prospective randomized trials are thus needed to further research in this area. In the present review we analyzed a number of clinical factors that are considered to predict recurrence or survival in HCC patients treated with RFA. We also discussed in detail the circulating biomarkers investigated to date, together with their potential to predict prognosis and recurrence after RFA therapy. Overall survival rates of patients with HCC are significantly affected by liver function, defined as Child-Pugh class, high baseline serum alpha-fetoprotein levels, and the presence of portosystemic collaterals. However, the development of local tumor progression does not significantly affect overall survival. This result is achieved by the effective therapies in patients who relapse after treatment with RFA. For this reason there is an urgent need to identify new circulating biomarkers.

show abstract

“…Specifically, genetic polymorphisms identified in genome-wide association studies and novel proteins identified by proteomic technology offer the possibility of the further refinement and individualization of biomarkers of hepatic fibrosis [7]. Moreover, metabolomics, the identification and quantification of all or specified metabolites in a living system under a specific condition or disease [12,13,15], might be a powerful platform for discovering novel biomarkers and biochemical pathways to improve the diagnosis, prognostication and treatment of hepatic fibrosis [16]. The current review thus summarizes recent findings of metabolic alterations relevant to hepatic fibrosis from the aspects of individual pathways and systems biology, including transcriptomics, proteomics, and metabolomics in vitro, in animal models and in humans.…”

Section: Introductionmentioning

confidence: 99%

Metabolic Signature of Hepatic Fibrosis: From Individual Pathways to Systems Biology

Chang

Yang

2019

Cells

View full text Add to dashboard Cite

Hepatic fibrosis is a major cause of morbidity and mortality worldwide, as it ultimately leads to cirrhosis, which is estimated to affect up to 2% of the global population. Hepatic fibrosis is confirmed by liver biopsy, and the erroneous nature of this technique necessitates the search for noninvasive alternatives. However, current biomarker algorithms for hepatic fibrosis have many limitations. Given that the liver is the largest organ and a major metabolic hub in the body, probing the metabolic signature of hepatic fibrosis holds promise for the discovery of new markers and therapeutic targets. Regarding individual metabolic pathways, accumulating evidence shows that hepatic fibrosis leads to alterations in carbohydrate metabolism, as aerobic glycolysis is aggravated in activated hepatic stellate cells (HSCs) and the whole fibrotic liver; in amino acid metabolism, as Fischer’s ratio (branched-chain amino acids/aromatic amino acids) decreases in patients with hepatic fibrosis; and in lipid metabolism, as HSCs lose vitamin A-containing lipid droplets during transdifferentiation, and cirrhotic patients have decreased serum lipids. The current review also summarizes recent findings of metabolic alterations relevant to hepatic fibrosis based on systems biology approaches, including transcriptomics, proteomics, and metabolomics in vitro, in animal models and in humans.

show abstract

Metabolomics: From liver chiromancy to personalized precision medicine in advanced chronic liver disease

Cited by 11 publications

References 50 publications

Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV‐coinfected and HCV‐monoinfected patients

Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV‐coinfected and HCV‐monoinfected patients

Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma

Metabolic Signature of Hepatic Fibrosis: From Individual Pathways to Systems Biology

Contact Info

Product

Resources

About